Heparin Re-exposure in HIT Patients

To evaluate heparin re-exposure practices and safety in patients with prior HIT.

Heparin-induced thrombocytopenia (HIT)–associated antibodies are transient, often declining to undetectable levels within approximately 3 to 6 months. Therefore, patients with a remote history of HIT are unlikely to retain immune memory to heparin.

This single-center retrospective study evaluated patients with prior HIT admitted between October 1, 2018, and September 30, 2024. HIT was defined as a positive serotonin-release assay result; a positive platelet factor 4 immunoassay result with optical density ≥0.4 units or a latex immunoturbidimetric assay ≥1 units/mL in the absence of a serotonin-release assay and treated as having HIT; or a documented diagnosis. The major outcome of this study was incidence of HIT recurrence in patients with a history of HIT who were re-exposed to heparin products on a subsequent admission. Minor outcomes included time from HIT diagnosis to heparin re-exposure, time from re-exposure to HIT recurrence, and incidence of in-hospital mortality, thrombotic event(s), or bleeding event(s) during a recurrent HIT episode.

Of the 35 patients who were re-exposed to heparin products, 1 (2.9%) developed recurrent HIT after 9 days of treatment with intravenous unfractionated heparin, without associated in-hospital mortality, thrombosis, or bleeding. Median time from first HIT diagnosis to heparin re-exposure was 8.1 years (IQR, 2.7-14.2 years).

These findings suggest that re-exposure to heparin products in patients with a remote history of HIT may be a safe option for patients requiring parenteral anticoagulation, given the low incidence of HIT recurrence.